- Home
- NFLX vs ABBV Comparison
NFLX vs ABBV Comparison
Compare NFLX & ABBV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NFLX | ABBV |
|---|---|---|
| Founded | 1997 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Video Chains | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 455.9B | 394.3B |
| IPO Year | 2002 | N/A |
Fundamental Metrics
Financial Performance| Metric | NFLX | ABBV |
|---|---|---|
| Price | $92.59 | $224.93 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 34 | 18 |
| Target Price | $130.91 | ★ $241.50 |
| AVG Volume (30 Days) | ★ 48.1M | 5.9M |
| Earning Date | 01-20-2026 | 01-30-2026 |
| Dividend Yield | N/A | ★ 3.07% |
| EPS Growth | ★ 35.54 | N/A |
| EPS | ★ 2.39 | 1.32 |
| Revenue | $43,378,787,000.00 | ★ $59,644,000,000.00 |
| Revenue This Year | $17.86 | $10.37 |
| Revenue Next Year | $12.94 | $9.41 |
| P/E Ratio | ★ $38.74 | $170.51 |
| Revenue Growth | ★ 15.41 | 7.40 |
| 52 Week Low | $82.11 | $164.39 |
| 52 Week High | $134.12 | $244.81 |
Technical Indicators
Market Signals| Indicator | NFLX | ABBV |
|---|---|---|
| Relative Strength Index (RSI) | 9.06 | 47.04 |
| Support Level | $95.30 | $220.23 |
| Resistance Level | $104.79 | $230.94 |
| Average True Range (ATR) | 3.44 | 5.13 |
| MACD | 21.37 | -0.80 |
| Stochastic Oscillator | 1.25 | 26.43 |
Price Performance
Historical ComparisonAbout NFLX Netflix Inc.
Netflix's relatively simple business model involves only one business, its streaming service. It has the biggest television entertainment subscriber base in both the United States and the collective international market, with more than 300 million subscribers globally. Netflix has exposure to nearly the entire global population outside of China. The firm has traditionally avoided a regular slate of live programming or sports content, instead focusing on on-demand access to episodic television, movies, and documentaries. The firm introduced ad-supported subscription plans in 2022, giving the firm exposure to the advertising market in addition to the subscription fees that have historically accounted for nearly all its revenue.
About ABBV AbbVie Inc.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.